AETC National Coordinating Resource Center

François-Xavier Bagnoud Center

School of Nursing, Rutgers, The State University of New Jersey
65 Bergen Street, 8th floor
Newark, NJ 07101
United States

Phone
(973) 972-5141
Fax
(973) 972-0397

The AETC National Coordinating Resource Center provides education, training, and capacity building resources for the AETC Program to support the mission to offer timely, high quality, state-of-the-science information to healthcare professionals working with existing and emerging populations affected by HIV.

Principal Investigator
Phone: (973) 972-5141
Fax: (973) 972-0397
Program Director
Phone: (973) 972-6268
Fax: (973) 972-4263
Program Manager
Phone: (973) 972-9225
Marketing Coordinator
Phone: (973) 972-5528

Resources: 37

Title Sort descending Publish Date Review Date
Assisting HIV Patients Returning to Mexico and Central America / Asistiendo a los Pacientes que Regresan a México y Centroamérica
Barriers to Curing Hepatitis C Virus among Coinfected People with HIV Infographic
Brand and Generic Names of ARVs in the United States and Mexico
Community Health Worker Training Resources
Conducting a Primary or Acute Care HIV Telemedicine Visit
COVID-19 Resources for HIV Providers
COVID-19, HIV, and Housing Instability
Direct-acting Antiviral (DAA) Prior Authorization Letter Templates
Evaluating AETC NCRC Partnerships for Impact
Federal COVID-19 Resources
Federal Training Centers Collaborative (FTCC) Virtual Learning Session Materials
Flyer: Hepatitis C Screening and Treatment in People with HIV
Hep C Free Postcard
Hepatitis C: Getting Cured Is Easier than Ever
HHS Adult ART Guidelines: HIV and ART in Older People
HHS Adult ART Guidelines: Initial Therapy
HHS Adult ART Guidelines: Transgender People with HIV
HHS Adult ART Guidelines: Treatment-Experienced Patients
HIV & SARS-CoV-2 Webinar Series
HIV Epidemic Rapid Response Toolkit
HIV/HCV Co-infection: An AETC National Curriculum
Integrating Behavioral Health into Primary HIV Care — Covering the Bases
Integrating Mental Health and Substance Use Care into HIV Primary Care Toolkit
Myths about Providing HCV Treatment to People with HIV with Substance Use Disorder(s)
New Pandemic, Old Inequities: Impacts of COVID-19 and HIV on Marginalized Populations
Non-Occupational Post-Exposure Prophylaxis (nPEP) Toolkit
Passport to Cure
Post COVID Syndrome: An Overview and Approach to Management
Prescribing nPEP Infographic
Prescribing PrEP: A Guide for Healthcare Providers
Rapid (Immediate) ART Initiation & Restart: Guide for Clinicians
Reaching People with HIV in Rural United States
Resources for Accessibility
Results and Response to a 10-State COVID-19 Practice Impact Survey in the Mountain West Region
Risk, Presentation, Treatment, and Outcomes of COVID-19 in People with HIV
Ryan White HIV/AIDS Program (RWHAP) Clinical Conference
Self-care, Resiliency, and Stress Management for Healthcare Providers

Articles: 51

Title Sort descending Publish date Review date
AETC Representation at the 2022 National Ryan White Conference on HIV Care & Treatment
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
Bictegravir in Initial Therapy
Bictegravir/TAF/FTC in Women
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
CROI 2017: Failure of Dolutegravir Monotherapy
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
Dolutegravir + 3TC in Initial Therapy
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine--New NNRTI Approved by FDA
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
HIV Care Tools – A New Resource for Ending the HIV Epidemic
HIV Meds Update - RAPID: Immediate ART Initiation
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
HIV-related Journal Articles by AETC-Affiliated Researchers and Faculty, 2019-2020
HIV-related Journal Articles from AETC-Affiliated Researchers and Faculty, 2021
Ibalizumab Approved for Persons with Multidrug Resistant HIV
Immediate ART Initiation Improves Time to Viral Suppression
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Long-acting Injectable PrEP Approved: Cabotegravir
Long-acting Injectable PrEP: Cabotegravir
Naltrexone Improves Virologic Suppression
New ARV Approval - Fostemsavir
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
PrEP: Bone Density Improves after Stopping TDF/FTC
PrEP: TDF/FTC vs TAF/FTC in MSM
Rapid ART Start
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Safety of Dolutegravir at Conception: Updated Data
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
Switching from TDF/FTC to TAF/FTC
TargetHIV: New Name, New Look
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Tips for Successful Linkage to Care
Tissue Levels of TAF: Too Low for PrEP?
U=U in PARTNER2 Study of MSM
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
Updated CDC PrEP Guidelines
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Use of Dolutegravir in Dialysis
Day Title
10/16 to 10/18 2022 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE (California)
Sunday, October 16, 2022 - 8:00am EDT to Tuesday, October 18, 2022 - 5:00pm EDT
Event type: Conferences & Events